(122 days)
The Accure Laser System is indicated for the treatment of mild to severe inflammatory acne vulgaris.
Not Found
The provided text is a 510(k) premarket notification letter from the FDA regarding the Accure Laser System. It does not contain any information about acceptance criteria or a study that proves the device meets specific performance criteria, especially not in the context of an AI/ML powered device, which is implied by the detailed questions about ground truth, training sets, and human-in-the-loop performance.
The document discusses:
- The FDA's determination of substantial equivalence to a predicate device.
- The regulatory classification (Class II, Product Code GEX).
- General controls provisions of the Act that apply to the device.
- Indications for Use (treatment of mild to severe inflammatory acne vulgaris).
Therefore, I cannot answer the specific questions about acceptance criteria, study details, sample sizes, expert qualifications, or ground truth establishment based on the provided text. The device described, the Accure Laser System, appears to be a hardware laser system, not an AI/ML-powered diagnostic or treatment device.
If you have information about a study or acceptance criteria for an AI/ML device related to this, please provide that text for analysis.
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.